Evaluation of 64Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Chemical Society"
DOI: 10.1021/jacs.7b05937
Abstract: Positron emission tomography (PET) imaging agents that detect amyloid plaques containing amyloid beta (Aβ) peptide aggregates in the brain of Alzheimer’s disease (AD) patients have been successfully developed and recently approved by the FDA for… read more here.
Keywords: based radiopharmaceuticals; alzheimer disease; peptide aggregates; 64cu based ... See more keywords
Rigid H4OCTAPA derivatives as model chelators for the development of Bi(III)-based radiopharmaceuticals.
Sign Up to like & getrecommendations! Published in 2023 at "Chemical communications"
DOI: 10.1039/d2cc06876a
Abstract: Octadentate ligands containing ethyl (H4OCTAPA), cyclohexyl (H4CHXOCTAPA) or cyclopentyl (H4CpOCTAPA) spacers were assessed as chelators for Bi(III)-based radiopharmaceuticals. The H4CHXOCTAPA chelator displays excellent properties, including 205/206Bi-nuclide radiolabelling under mild conditions, excellent stability in serum and… read more here.
Keywords: h4octapa derivatives; derivatives model; based radiopharmaceuticals; iii based ... See more keywords
Antibody-based radiopharmaceuticals as theranostic agents: an overview.
Sign Up to like & getrecommendations! Published in 2022 at "Current medicinal chemistry"
DOI: 10.2174/0929867329666220607160559
Abstract: Since the inception of antibodies as magic bullets for targeting antigens with high specificity for various in vitro and in-vivo detection and therapy applications, the field has evolved and remarkable success has been achieved not… read more here.
Keywords: intact antibodies; development; antibody based; therapy ... See more keywords
Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24119154
Abstract: Copper-64 (T1/2 = 12.7 h) is a positron and beta-emitting isotope, with decay characteristics suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer. Copper-67 (T1/2 = 61.8 h) is a beta and… read more here.
Keywords: copper; imaging radiotherapy; based radiopharmaceuticals; 64cu 67cu ... See more keywords
Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15060723
Abstract: PET imaging has gained significant momentum in the last few years, especially in the area of oncology, with an increasing focus on metal radioisotopes owing to their versatile chemistry and favourable physical properties. Copper-61 (t1/2… read more here.
Keywords: liquid targets; gmp compliant; clinical amounts; production ... See more keywords
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15041240
Abstract: Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) based radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine and oncology, allowing for personalized medicine. Since the first market authorization in 2018… read more here.
Keywords: therapeutic optimization; lutetium 177; safety therapeutic; based radiopharmaceuticals ... See more keywords